

| CERTIFICATE OF EFS TRANSMISSION | | |
|---|--|---|
| <p>I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being transmitted to the United States Patent and Trademark Office on the date shown below via the "Electronic Filing System" in accordance with 37 C.F.R. § 1.6(a)(4).</p> | | |
| <u>Kristin Miele</u> <small>Type or print name</small> | <u>/Kristin Miele/</u> <small>Signature</small> | <u>July 28, 2009</u> <small>Date</small> |

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|------------|---|-----------|------------|
| Applicants | : Mark Tawa et al. | Conf. No. | 4554 |
| Serial No. | : 10/541,216 | Art Unit: | 1617 |
| Filed | : June 29, 2005 | Examiner: | D. Claytor |
| For | : PHARMACEUTICAL COMPOSITIONS WITH IMPROVED DISSOLUTION | | |

I hereby certify that this submission contains the following:

- | | | |
|-------------------------------------|---|--|
| <input checked="" type="checkbox"/> | Supplemental Information Disclosure Statement | (2 pages) |
| <input checked="" type="checkbox"/> | Form 1449 | (35 pages) |
| <input checked="" type="checkbox"/> | References | (36 total in this EFS submission) |
| <input checked="" type="checkbox"/> | References | (50 to be submitted in second EFS submission today) |
| <input checked="" type="checkbox"/> | References | (50 to be submitted in third EFS submission today) |
| <input checked="" type="checkbox"/> | References | (50 to be submitted in fourth EFS submission today) |
| <input checked="" type="checkbox"/> | References | (50 to be submitted in fifth EFS submission today) |
| <input checked="" type="checkbox"/> | References | (50 to be submitted in sixth EFS submission today) |
| <input checked="" type="checkbox"/> | References | (50 to be submitted in seventh EFS submission today) |
| <input checked="" type="checkbox"/> | References | (13 to be submitted in eighth EFS submission today) |